Cargando…

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression

Major depressive disorder has become a prominent cause of disability, as lifetime prevalence has increased to ~15% in the Western world. Pharmacological effects of serotonin (5-hydroxytryptamine, 5-HT) are mediated through 5-hydroxytryptamine receptor (5-HTR) binding. Serotonin regulation of amygdal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochi, Taichi, Vyalova, Natalya M., Losenkov, Innokentiy S., Paderina, Diana Z., Pozhidaev, Ivan V., Loonen, Anton J. M., Simutkin, German G., Bokhan, Nikolay A., Ivanova, Svetlana A., Wilffert, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951408/ https://www.ncbi.nlm.nih.gov/pubmed/31956308 http://dx.doi.org/10.3389/fphar.2019.01462

Ejemplares similares

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
por: Ochi, Taichi, et al.
Publicado: (2021)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
por: Geers, Lisanne M., et al.
Publicado: (2021)

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
por: Levchenko, Anastasia, et al.
Publicado: (2018)

Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
por: Losenkov, Innokentiy S., et al.
Publicado: (2020)

A New Paradigm to Indicate Antidepressant Treatments
por: Loonen, Anton J. M., et al.
Publicado: (2021)

Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
por: Roschina, Olga V., et al.
Publicado: (2021)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
por: Levchenko, Anastasia, et al.
Publicado: (2020)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
por: Mikhalitskaya, Ekaterina V., et al.
Publicado: (2023)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
por: Levchuk, Lyudmila A., et al.
Publicado: (2020)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2020)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Exploring the paradigm of depressive disorders through an evolutionary and biopsychosocial lens
por: Ochi, T., et al.
Publicado: (2023)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
por: Levchuk, Lyudmila A., et al.
Publicado: (2023)

Drug-induced metabolic syndrome hasn’t associations with 5-HT receptor genes polymorphisms in patients with schizophrenia
por: Paderina, D., et al.
Publicado: (2021)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Neuron-specific enolase during the therapy in patients with alcohol use disorder and mood disorders
por: Levchuk, L., et al.
Publicado: (2021)

Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
por: Fedorenko, Olga Yu., et al.
Publicado: (2021)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
por: Ivanova, Svetlana A, et al.
Publicado: (2016)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
por: Boiko, A., et al.
Publicado: (2021)

Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2021)

SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
por: Aftanas, Lyubomir I., et al.
Publicado: (2019)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
por: Ivanova, Svetlana A., et al.
Publicado: (2018)

Clinical dynamics of anhedonia symptom in mood disorder and in alcohol use disorder
por: Roshchina, O., et al.
Publicado: (2021)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e9cavtn4fauhq679l4ef9p2uas